Abstract. Gastric cancer is one of the leading causes of cancer-related mortality worldwide. Loss of programmed cell death 4 (PDCD4) expression has been detected in gastric cancer. However, the effects of PDCD4 on pT2 stage gastric cancer remain unclear. The aim of this study was to identify the relationship between PDCD4 expression and clinicopathological features of patients with pT2 stage gastric cancer. In the present study, 122 pT2 stage gastric cancer specimens were subclassified as pT2a and pT2b stage. The levels of PDCD4 mRNA and protein in gastric cancer tissues were lower compared to that in normal tissues as detected by real-time PCR and western blot analysis, respectively. In addition, both PDCD4 mRNA and protein in pT2b stage gastric cancer were lower when compared to that in pT2a stage gastric cancer. Finally, we used immuno histochemistry to determine the protein expression and analyzed the relationship between PDCD4 expression and the clinicopathological features of pT2 stage gastric cancer patients. Cumulative survival rate of patients with PDCD4 expression was significantly higher compared to the patients without PDCD4 expression. PDCD4 expression in gastric cancer can be employed to indicate a favorable prognosis for the disease outcome.
Introduction
Gastric cancer is one of the leading causes of cancer-related mortality worldwide. A total of 989,600 new stomach cancer cases and 738,000 deaths are estimated to have occurred in 2008, accounting for 8% of the total cases and 10% of total deaths (1) . Depth of invasion and lymph node status or optimization of pT (primary tumor) and pN (regional lymph nodes) category are important prognostic factors for gastric cancer (2) (3) (4) . In 2002, the 6th edition of the International Union Against Cancer (UICC)/American Joint Committee on Cancer (AJCC) further divided pT2 gastric adenocarcinomas into type pT2a [invasion of the muscularis propria (MP)] and type pT2b [invasion of the subserosa (SS)] (5). Moreover, previous studies have clearly demonstrated that multiple genetic alterations are responsible for the development and progression of gastric cancer similar to other human cancers (6, 7) .
Programmed cell death 4 (PDCD4) has been demonstrated to inhibit tumor promoter-induced neoplastic transformation in a murine JB6 cell model system (8) . The human PDCD4 gene was found to be localized on chromosome 10q24 (9) . Its encoding product is a 64-kDa protein involved in the apoptotic machinery, which suppresses cell transformation, tumorigenesis and invasion (10) (11) (12) . PDCD4 is expressed in many normal tissues, such as normal mammary gland and normal human lung tissue (13, 14) . Its levels were found to be markedly decreased in primary patient tumor samples from lung cancer (14) , breast carcinoma (10), colon cancer (15) and hepatocellular carcinoma (16) .
Previous research has demonstrated the relationship between gastric cancer and PDCD4 (17) . However, to the best of our knowledge no studies have shown whether PDCD4 is associated with pT2a and pT2b stage gastric cancers. In the present study, gastric cancer specimens were classified as stages pT2a and pT2b and the levels of PDCD4 mRNA and protein were evaluated. Finally, we used immunohistochemistry to determine the expression of PDCD4 protein and analyzed the relationship between PDCD4 expression and the clinicopathological features of the patients with pT2 stage gastric cancer.
Patients and methods

Subjects.
Specimens from 122 patients with pT2 stage gastric cancer were obtained from the Department of Surgical Oncology, First Affiliated Hospital, China Medical University (Shenyang, China) from January 2001 to December 2010 and classified into pT2a and pT2b stages according to the UICC/AJCC pT staging system. None of the patients underwent radiotherapy or chemotherapy prior to surgery. This study was in compliance with the Helsinki Declaration. All patients provided written informed consent for participation, and the procedure was approved by our university ethics committee. Immunohistochemical staining. Immunohistochemistry was used to detect the expression of PDCD4 protein in gastric cancer samples. The study population included 122 patients as described above. Immunohistochemical staining was performed on 4-µm sections obtained from formalin-fixed, paraffin-embedded blocks. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide for 30 min. Antigen retrieval was carried out in citrate buffer (10 mM, pH 6.0) for 30 min at 95˚C. PDCD4 antibody (Cell Signaling Technology) at a dilution of 1:500 was applied and sections were incubated at 4˚C overnight. Afterward, sections were incubated with a biotinylated secondary antibody and then exposed to a streptavidin complex (HRP). Positive reactions were visualized with 3,3'-diaminobenzidine tetrahydrochloride (DAB; Sigma-Aldrich), followed by counterstaining with hematoxylin. Normal tissue was used as a control. Sections treated without primary antibodies were used as negative controls. The percentage of positive-stained cells was graded semiquantitatively according to a four-tier scoring system: negative (-), 0-5%; weakly positive (+), 6-25%; moderately positive (++), 26-50% and strongly positive (+++), 51-100%.
PDCD4 functions as a suppressor for pT2a and pT2b stage gastric cancer
Cell cycle distribution and analysis of apoptosis. pT2a and pT2b gastric cancer samples and paired normal tissues were subjected to chemical digestion by incubation with 0.5% pepsin (pH 1.5; Sigma-Aldrich) at 37˚C in a water bath for 30 min with intermittent stirring. Disaggregated tissues were filtered through a 50-µm nylon mesh, washed twice with PBS and re-suspended in PBS. Cells were collected in PBS and fixed on ice with 1% paraformaldehyde, followed by 70% cold ethanol. After treatment with 10 µg/ml RNase, the cells were stained with 50 µg/ml propidium iodide (PI; KeyGen, Nanjing, Statistical analysis. All statistical analyses and graphics were performed using GraphPad Prism 5. Overall survival rates were determined using the Kaplan-Meier estimator. Kaplan-Meier survival plots were generated and comparisons were made with log-rank statistics. Cox's proportional hazard model was used to identify significant factors correlated with prognosis in multivariate analysis. For all analyses, P<0.05 was considered to indicate a statistically significant result.
Results
Evaluation of the levels of PDCD4 mRNA and protein in pT2a and pT2b stage gastric cancer specimens. Real-time PCR was carried out to investigate the level of PDCD4 mRNA in gastric cancer specimens. The results indicated that the level of PDCD4 mRNA was lower in the gastric cancer specimens compared to that in the normal tissues (P<0.05; Fig. 1A ). To examine the relationship between the level of PDCD4 protein and the level of PDCD4 transcription, western blot analysis of the PDCD4 protein was carried out in gastric cancer specimens and the results showed that the level of PDCD4 protein was lower compared to that in the normal tissues and coincident with the level of mRNA (P<0.05; Fig. 1B) . Notably, the levels of PDCD4 mRNA and protein were higher in pT2a stage cancer tissues compared with that in pT2b stage cancer tissues (Figs. 1 and 2 ).
PDCD4 expression is correlated with clinicopathological parameters of the patients with pT2 stage gastric cancer.
The immunostaining results showed that PDCD4 expression was distributed in the cytoplasm of normal gastric and gastric cancer cells (Fig. 2) . However, PDCD4 protein was weakly expressed in the gastric cancer tissues, while highly in the corresponding normal tissues. There was a significant difference in PDCD4 expression between the normal gastric tissues, when compared with that in the pT2a and pT2b stage gastric cancer tissues (P<0.05; Table I ). We then analyzed the potential relationship between the expression of PDCD4 and the clinico pathological characteristics of these patients. The results are summarized in Table II . No correlation was found with patient gender, age, lymphatic invasion, venous Table I . PDCD4 expression in the normal gastric tissues and pT2a and pT2b stage gastric cancer tissue. Fig. 3A) . Notably, the major clinical distinction between pT2a stage gastric cancer patients and pT2b stage gastric cancer patients was that PDCD4 expression showed no statistically significant effects on pT2b patient survival (P>0.05; Fig. 3C ) when compared with the pT2a patients (P<0.05; Fig. 3B ). Cox's proportional hazard analysis indicated that PDCD4 was an independent prognostic factor Table II . Relationship between PDCD4 expression and clinicopathological parameters of the patients with pT2 stage gastric cancer. 
PDCD4 expression --------------------------------------------------------------------
PDCD4 expression Clinicopathological ---------------------------------------------------------------------
Discussion
In the present study, levels of PDCD4 mRNA and protein expression were assessed in a total of 122 gastric cancer tissue specimens. We demonstrated a decreasing trend for both mRNA and protein expression of PDCD4 in pT2a and pT2b stage gastric cancer tissues. Motoyama et al (17) demonstrated through a panel of primary specimens and cell culture models that PDCD4 mRNA/protein expression is lower in gastric cancer tissues compared to corresponding normal tissues. This indicates that PDCD4 may play a role in human gastric carcinogenesis. Notably, we also found that the levels of mRNA and protein expression of PDCD4 were higher in pT2a gastric cancer tissues than that in pT2b gastric cancer tissues. Consistent with a previous study, reduced expression of PDCD4 is related to advanced tumor stage in gastric cancer (17) . Loss of PDCD4 in lung cancer was correlated with higher histological grade, disease stage and poor prognosis (14) . In our study, loss of PDCD4 expression was significantly associated with differentiation and tumor size of both pT2a and pT2b stage gastric cancer tissues. Previous studies have demonstrated that PDCD4 is an independent risk factor in lung (14) and colon cancer (15, 18) . However, to the best of our knowledge, no similar studies have been carried out in gastric cancer. We initially found that PDCD4 was an independent risk factor in pT2 stage gastric cancer. Furthermore, we confirmed that reduced PDCD4 expression was significantly associated with low overall survival rate. There is no doubt that reduced PDCD4 is a negative prognostic factor in primary lung cancer (14) , colon cancer (15), ovarian cancer (19) and glioma (20) . However, we found that reduced PDCD4 did not affect the survival of pT2b stage gastric cancer patients. The reason may be that the level of PDCD4 protein in pT2b stage gastric cancer patients is too low to exert a function. PDCD4 has been reported as an inducer of apoptosis (21, 22) . In our study, we confirmed that cells obtained from pT2a tumor specimens had a higher apoptotic ratio than cells from pT2b tumor tissue specimens. This indicates that PDCD4 induces apoptosis in gastric cancer cells. In addition, we also found that PDCD4 inhibits the cell cycle. Cells obtained from pT2a tumor tissue specimens consisted of a small percentage of cells in the G 2 phase when compared to cells from pT2b tumor tissue specimens. To our knowledge, this is the first report concerning the relationship between PDCD4 and the cell cycle in gastric cancer.
Taken together, we demonstrated that PDCD4 is associated with pT2 stage gastric cancer. The results are not only of relevance for diagnosis and prognosis, but may also provide a novel target for pT2a and pT2b stage gastric cancer therapies.
